The 10-second takeaway
For the quarter ended March 31 (Q1), Sagent Pharmaceuticals beat expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue grew significantly. Non-GAAP earnings per share increased. GAAP earnings per share grew.
Margins grew across the board.
Sagent Pharmaceuticals logged revenue of $60.2 million. The seven analysts polled by S&P Capital IQ expected to see net sales of $55.3 million on the same basis. GAAP reported sales were 57% higher than the prior-year quarter's $38.3 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.17. The eight earnings estimates compiled by S&P Capital IQ anticipated -$0.03 per share. Non-GAAP EPS were $0.17 for Q1 versus -$0.30 per share for the prior-year quarter. GAAP EPS were $0.34 for Q1 against -$0.30 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 30.7%, much better than the prior-year quarter. Operating margin was 17.2%, much better than the prior-year quarter. Net margin was 16.3%, much better than the prior-year quarter. (Margins calculated in GAAP terms.)
Next quarter's average estimate for revenue is $57.6 million. On the bottom line, the average EPS estimate is $0.00.
Next year's average estimate for revenue is $238.1 million. The average EPS estimate is $0.09.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Sagent Pharmaceuticals is outperform, with an average price target of $19.13.
- Add Sagent Pharmaceuticals to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.